Suzuki Y, et al. – This research entailed the determination of the clinicopathological features of CD4+ and/or CD56+ immature hematolymphoid malignancy (iHLM), including blastic plasmacytoid dendritic cell neoplasm (BPDCN). The findings validated the recognition of cutaneous BPDCN as a homogenous entity, in opposition to the non–cutaneous form. The characterization of non–BPDCN–type CD56+ neoplasms necessitated advanced research.